Linked Life Data

21083700

Source:http://linkedlifedata.com/resource/pubmed/id/21083700

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2011-1-4
pubmed:abstractText
1. Recent reports have described the role of osteocalcin in glucose metabolism and glycaemic variability has been proven to be associated with an increased risk of diabetes complications. However, the relationship between osteocalcin and glycaemic variability remains unclear. The aim of the present study was to examine the relationship between serum osteocalcin and glycaemic variability, as determined by a continuous glucose monitoring (CGM) system in patients with Type 2 diabetes mellitus (T2DM). 2. Fifty-nine T2DM patients with glycosylated haemoglobin (HbA1c) levels between 7.0% and 10.9% were recruited to the present study. Biochemical information and CGM parameters were collected at baseline and after 8 weeks of antihyperglycaemic therapy (either sulphonylurea, sulphonylurea + an ?-glucosidase inhibitor or insulin + metformin combination therapy). 3. Compared with baseline, serum osteocalcin increased significantly (P = 0.014), whereas parameters related to glucose variability, including the mean amplitude of glycaemic excursions (MAGE) and the standard deviation of blood glucose values, decreased significantly (P < 0.001) after the 8 week treatment period. At baseline, there was a positive correlation between serum osteocalcin levels and fasting C-peptide levels (P = 0.004) and homeostatic model assessment of ?-cell function (P = 0.048), but a negative correlation between serum osteocalcin levels and fasting plasma glucose (P = 0.023), HbA1c (P = 0.020), glycated albumin (P = 0.019) and 24 h mean blood glucose (P < 0.001). Multiple stepwise regression analysis indicated that baseline osteocalcin was the single parameter that best predicted the change in MAGE (? = -0.122; P = 0.039). 4. In conclusion, serum osteocalcin concentrations increased with improved glucose control. High initial osteocalcin levels were associated with subsequent improvements in glucose variability during glucose-lowering treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1440-1681
pubmed:author
pubmed:copyrightInfo
© 2010 The Authors. Clinical and Experimental Pharmacology and Physiology © 2010 Blackwell Publishing Asia Pty Ltd.
pubmed:issnType
Electronic
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
50-4
pubmed:meshHeading
pubmed-meshheading:21083700-Adult, pubmed-meshheading:21083700-Aged, pubmed-meshheading:21083700-Blood Glucose, pubmed-meshheading:21083700-Blood Glucose Self-Monitoring, pubmed-meshheading:21083700-Diabetes Mellitus, Type 2, pubmed-meshheading:21083700-Enzyme Inhibitors, pubmed-meshheading:21083700-Female, pubmed-meshheading:21083700-Hemoglobin A, Glycosylated, pubmed-meshheading:21083700-Humans, pubmed-meshheading:21083700-Hypoglycemic Agents, pubmed-meshheading:21083700-Individuality, pubmed-meshheading:21083700-Lipid Metabolism, pubmed-meshheading:21083700-Male, pubmed-meshheading:21083700-Metformin, pubmed-meshheading:21083700-Middle Aged, pubmed-meshheading:21083700-Observer Variation, pubmed-meshheading:21083700-Osteocalcin, pubmed-meshheading:21083700-Sulfonylurea Compounds, pubmed-meshheading:21083700-alpha-Glucosidases
pubmed:year
2011
pubmed:articleTitle
Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes.
pubmed:affiliation
Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai, China.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't